| 527 | Parkinson's disease |
| 332 | Humans |
| 219 | Parkinson disease |
| 218 | Male |
| 205 | Middle Aged |
| 204 | Female |
| 185 | Aged |
| 128 | Human |
| 115 | Adult |
| 94 | Parkinson Disease (drug therapy) |
| 91 | Parkinson Disease (physiopathology) |
| 86 | Nervous system diseases |
| 81 | Parkinson Disease (genetics) |
| 75 | essential tremor |
| 69 | dystonia |
| 69 | deep brain stimulation |
| 62 | Parkinson’s disease |
| 53 | Parkinson Disease (complications) |
| 52 | Treatment |
| 51 | parkinsonism |
| 51 | Parkinson Disease (diagnosis) |
| 47 | Aged, 80 and over |
| 44 | genetics |
| 42 | levodopa |
| 40 | Tremor |
| 40 | Treatment Outcome |
| 40 | Severity of Illness Index |
| 38 | tremor |
| 38 | multiple system atrophy |
| 38 | dopamine |
| 37 | Antiparkinson Agents (therapeutic use) |
| 35 | Follow-Up Studies |
| 35 | Double-Blind Method |
| 34 | Parkinsonism |
| 34 | Parkinson Disease (epidemiology) |
| 34 | Levodopa (therapeutic use) |
| 32 | Chemotherapy |
| 31 | restless legs syndrome |
| 30 | subthalamic nucleus |
| 29 | progressive supranuclear palsy |
| 29 | Levodopa |
| 28 | depression |
| 27 | epidemiology |
| 27 | Parkinson Disease (therapy) |
| 27 | Parkinson Disease (surgery) |
| 27 | Mutation |
| 25 | dementia |
| 25 | Risk Factors |
| 25 | Genotype |
| 24 | Animals |
| 24 | Age of Onset |
| 23 | Disease Progression |
| 23 | Antiparkinson agent |
| 21 | Time Factors |
| 20 | Parkinson Disease (psychology) |
| 20 | Parkinson Disease (pathology) |
| 20 | Diagnosis, Differential |
| 20 | Cohort Studies |
| 19 | basal ganglia |
| 19 | Neuropsychological Tests |
| 19 | Dystonia |
| 19 | Case-Control Studies |
| 18 | pallidotomy |
| 18 | neuroprotection |
| 18 | neurodegeneration |
| 18 | movement disorders |
| 18 | dyskinesia |
| 18 | dopamine agonists |
| 18 | Prospective Studies |
| 18 | Huntington's disease |
| 18 | Evolution |
| 18 | Complication |
| 18 | Antiparkinson Agents (adverse effects) |
| 18 | Adolescent |
| 17 | Parkinson Disease (metabolism) |
| 17 | PET |
| 17 | Levodopa (adverse effects) |
| 17 | LRRK2 |
| 17 | Brain (pathology) |
| 16 | Neurologic Examination |
| 16 | MPTP |
| 16 | Genetic Predisposition to Disease |
| 16 | Dopamine |
| 15 | treatment |
| 15 | globus pallidus |
| 15 | diagnosis |
| 15 | Retrospective Studies |
| 15 | Nerve Tissue Proteins (genetics) |
| 15 | Globus Pallidus (surgery) |
| 15 | Genetic Predisposition to Disease (genetics) |
| 14 | α‐synuclein |
| 14 | gait |
| 14 | dyskinesias |
| 14 | SPECT |
| 14 | Pergolide |
| 14 | Parkinson |
| 14 | Neuroprotective Agents (therapeutic use) |
| 14 | Dose-Response Relationship, Drug |
| 14 | Dopamine Agonists (therapeutic use) |
| 14 | Diagnosis |
| 14 | DNA Mutational Analysis |
| 14 | Alzheimer disease |
| 13 | quality of life |
| 13 | United States |
| 13 | Toxicity |
| 13 | Parkinson Disease (etiology) |
| 13 | Mutation (genetics) |
| 13 | Multiple system atrophy |
| 13 | Lewy body |
| 13 | Gene Frequency |
| 13 | Dyskinesia |
| 13 | Disability Evaluation |
| 12 | prevalence |
| 12 | pathophysiology |
| 12 | myoclonus |
| 12 | mutation |
| 12 | Risk factor |
| 12 | Predictive Value of Tests |
| 12 | Pathogenesis |
| 12 | PD, Parkinson’s disease |
| 12 | Essential Tremor (genetics) |
| 12 | Dopamine (metabolism) |
| 12 | Deep brain stimulation |
| 12 | Comparative study |
| 12 | Age Factors |
| 11 | risk factors |
| 11 | parkin |
| 11 | dopamine transporter |
| 11 | corticobasal degeneration |
| 11 | cerebrospinal fluid |
| 11 | camptocormia |
| 11 | botulinum toxin |
| 11 | Protein-Serine-Threonine Kinases (genetics) |
| 11 | Progressive supranuclear palsy |
| 11 | Phenotype |
| 11 | Pathophysiology |
| 11 | Pallidum |
| 11 | Longitudinal Studies |
| 11 | Essential |
| 11 | Antiparkinson Agents (administration & dosage) |
| 10 | vascular parkinsonism |
| 10 | transcranial magnetic stimulation |
| 10 | rating scales |
| 10 | chorea |
| 10 | Surgery |
| 10 | Review |
| 10 | Prognosis |
| 10 | Polymorphism, Single Nucleotide |
| 10 | Nurr1 |
| 10 | Neuroprotective Agents (pharmacology) |
| 10 | L‐dopa |
| 10 | Gait |
| 10 | Dopaminergic neuron |
| 10 | DBS |
| 10 | Clinical Trials as Topic |
| 10 | Cerebrospinal fluid |
| 10 | Brain (physiopathology) |
| 9 | thalamus |
| 9 | substantia nigra |
| 9 | striatum |
| 9 | sleep |
| 9 | pramipexole |
| 9 | motor fluctuations |
| 9 | motor complications |
| 9 | falls |
| 9 | dopamine agonist |
| 9 | clinical trial |
| 9 | cervical dystonia |
| 9 | association |
| 9 | Thalamus |
| 9 | Surveys and Questionnaires |
| 9 | Posture |
| 9 | Pedigree |
| 9 | Parkinson Disease, Secondary (chemically induced) |
| 9 | Parkinson Disease (cerebrospinal fluid) |
| 9 | PD |
| 9 | Magnetic Resonance Imaging |
| 9 | Gait disorder |
| 9 | Dyskinesia, Drug-Induced (etiology) |
| 9 | Degenerative disease |
| 9 | Cognition Disorders (etiology) |
| 9 | Alleles |
| 9 | Agonist |
| 8 | tics |
| 8 | thalamotomy |
| 8 | progression |
| 8 | neuroleptics |
| 8 | dementia with Lewy bodies |
| 8 | cognition |
| 8 | cerebellum |
| 8 | ataxia |
| 8 | UPDRS |
| 8 | Transcription Factors (genetics) |
| 8 | Thiophenes (administration & dosage) |
| 8 | Tetrahydronaphthalenes (administration & dosage) |
| 8 | Subthalamic nucleus |
| 8 | Substantia nigra |
| 8 | Sex Factors |
| 8 | Polymorphism, Single Nucleotide (genetics) |
| 8 | Parkin |
| 8 | PSP |
| 8 | MRI |
| 8 | Levodopa (administration & dosage) |
| 8 | Haplotypes |
| 8 | Genetics |
| 8 | Genetic determinism |
| 8 | Genetic Variation (genetics) |
| 8 | Epidemiology |
| 8 | Drug Therapy, Combination |
| 8 | Drug Administration Schedule |
| 8 | Dopamine receptor |
| 8 | Cognition |
| 8 | Case study |
| 8 | Animal |
| 8 | Alzheimer's disease |
| 8 | Administration, Cutaneous |
| 8 | Activities of Daily Living |
| 7 | serotonin |
| 7 | psychosis |
| 7 | polymorphism |
| 7 | neurodegenerative diseases |
| 7 | multiple sclerosis |
| 7 | mortality |
| 7 | disease progression |
| 7 | disability |
| 7 | differential diagnosis |
| 7 | clinical features |
| 7 | balance |
| 7 | association study |
| 7 | Tremor (physiopathology) |
| 7 | Tremor (etiology) |
| 7 | Tourette syndrome |
| 7 | Symptomatology |
| 7 | Striatum |
| 7 | STN, subthalamic nucleus |
| 7 | Prevalence |
| 7 | Positron emission tomography |
| 7 | Polymorphism |
| 7 | Parkinson Disease (ethnology) |
| 7 | Pallidotomy |
| 7 | PINK1 |
| 7 | Neuroprotective agent |
| 7 | Neurons (metabolism) |
| 7 | Movement Disorders (therapy) |
| 7 | Lewy bodies |
| 7 | LINGO1 |
| 7 | Gene |
| 7 | Exploration |
| 7 | Essential Tremor (physiopathology) |
| 7 | Essential Tremor (epidemiology) |
| 7 | Essential Tremor (complications) |
| 7 | Dopamine agonist |
| 7 | Dopamine Agonists (adverse effects) |
| 7 | Differential diagnostic |
| 7 | Depression |
| 7 | Benzothiazoles |
| 6 | tyrosine hydroxylase |
| 6 | transcranial sonography |
| 6 | therapy |
| 6 | surgery |
| 6 | prognosis |
| 6 | polysomnography |
| 6 | orthostatic tremor |
| 6 | olfaction |
| 6 | magnetic resonance imaging |
| 6 | human |
| 6 | gene therapy |
| 6 | freezing of gait |
| 6 | excessive daytime sleepiness |
| 6 | cancer |
| 6 | Young Adult |
| 6 | United States (epidemiology) |
| 6 | Unilateral |
| 6 | Unified Parkinson's Disease Rating Scale |
| 6 | Tremor (genetics) |
| 6 | Tremor (complications) |
| 6 | Supranuclear Palsy, Progressive (physiopathology) |
| 6 | Sensitivity and Specificity |
| 6 | Selegiline |
| 6 | Selegiline (therapeutic use) |
| 6 | Risk |
| 6 | Reproducibility of Results |
| 6 | Quality of Life |
| 6 | Proportional Hazards Models |
| 6 | Pramipexole |
| 6 | Polymorphism, Genetic |
| 6 | Polymerase Chain Reaction |
| 6 | PD, Parkinson's disease |
| 6 | Odds Ratio |
| 6 | Nuclear Receptor Subfamily 4, Group A, Member 2 |
| 6 | Mouse |
| 6 | Mice |
| 6 | Mechanism of action |
| 6 | Genetic Testing |
| 6 | Essential tremor |
| 6 | Dopamine Agonists (administration & dosage) |
| 6 | Dementia |
| 6 | Deep Brain Stimulation (adverse effects) |
| 6 | Comorbidity |
| 6 | Brain (metabolism) |
| 6 | Biomarkers (cerebrospinal fluid) |
| 6 | Basal ganglion |
| 6 | Animal model |
| 5 | weight gain |
| 5 | voxel‐based morphometry |
| 5 | stroke |
| 5 | stereotaxy |
| 5 | sleep disorders |
| 5 | review |
| 5 | postural instability |
| 5 | pain |
| 5 | oxidative stress |
| 5 | neurophysiology |
| 5 | movement disorder |
| 5 | hallucinations |
| 5 | globus pallidus internus |
| 5 | gait disorder |
| 5 | focal dystonia |
| 5 | family history |
| 5 | exercise |
| 5 | electromyography |
| 5 | daytime sleepiness |
| 5 | cognitive impairment |
| 5 | clinimetrics |
| 5 | cerebellar ataxia |
| 5 | blepharospasm |
| 5 | biomarker |
| 5 | apoptosis |
| 5 | anxiety |
| 5 | amyotrophic lateral sclerosis |
| 5 | amantadine |
| 5 | alpha‐synuclein |
| 5 | alpha-Synuclein (genetics) |
| 5 | aging |
| 5 | age at onset |
| 5 | UPDRS, Unified Parkinson’s Disease Rating Scale |
| 5 | Tremor (diagnosis) |
| 5 | Treatment efficiency |
| 5 | Tomography, X-Ray Computed |
| 5 | Thalamotomy |
| 5 | Tardive dyskinesia |
| 5 | Syndrome |
| 5 | Stereotaxic surgery |
| 5 | Stereotaxic Techniques |
| 5 | Somnolence |
| 5 | Reverse Transcriptase Polymerase Chain Reaction |
| 5 | Receptors, Dopamine (metabolism) |
| 5 | Prevention |
| 5 | Postoperative |
| 5 | Parkinson Disease (blood) |
| 5 | PSP, progressive supranuclear palsy |
| 5 | Nuclear magnetic resonance imaging |
| 5 | Movement Disorders (physiopathology) |
| 5 | Movement Disorders (drug therapy) |
| 5 | Movement Disorders (diagnosis) |
| 5 | Long term |
| 5 | Huntington disease |
| 5 | Genetic Variation |
| 5 | Functional Laterality |
| 5 | Freezing |
| 5 | European Continental Ancestry Group (genetics) |
| 5 | Essential Tremor (diagnosis) |
| 5 | Ergolines (therapeutic use) |
| 5 | Dystonia (physiopathology) |
| 5 | Dystonia (etiology) |
| 5 | Dystonia (complications) |
| 5 | Dyskinesias |
| 5 | Degeneration |
| 5 | Deep Brain Stimulation |
| 5 | Deep Brain Stimulation (methods) |
| 5 | DYT1 |
| 5 | Cross-Sectional Studies |
| 5 | Cognition Disorders (diagnosis) |
| 5 | Child |
| 5 | Carrier Proteins (genetics) |
| 5 | Carbidopa (therapeutic use) |
| 5 | Carbidopa (administration & dosage) |
| 5 | Basal Ganglia (physiopathology) |
| 5 | Apoptosis |
| 5 | Antipsychotic Agents (therapeutic use) |
| 5 | Alzheimer Disease (cerebrospinal fluid) |
| 5 | ALS |
| 4 | transplantation |
| 4 | torsinA |
| 4 | thalamic stimulation |
| 4 | tauopathy |
| 4 | tau |
| 4 | tau Proteins (cerebrospinal fluid) |
| 4 | tardive dyskinesia |
| 4 | synucleinopathy |
| 4 | subthalamotomy |
| 4 | smoking |
| 4 | sleep disturbance |
| 4 | sialorrhea |
| 4 | schizophrenia |
| 4 | rigidity |
| 4 | rasagiline |
| 4 | putamen |
| 4 | postural control |
| 4 | positron emission tomography |
| 4 | physical therapy |
| 4 | phenotype |
| 4 | pallidal stimulation |
| 4 | nonmotor symptoms |
| 4 | neuropsychology |
| 4 | neuropathology |
| 4 | motor symptoms |
| 4 | mitochondria |
| 4 | mild cognitive impairment |
| 4 | microelectrode recording |
| 4 | linkage |
| 4 | impulse control disorders |
| 4 | hemifacial spasm |
| 4 | hallucination |
| 4 | frontotemporal dementia |
| 4 | fatigue |
| 4 | deprenyl |
| 4 | clozapine |
| 4 | clinical trials |
| 4 | bradykinesia |
| 4 | botulinum toxin A |
| 4 | bent spine |
| 4 | autonomic dysfunction |
| 4 | atypical parkinsonism |
| 4 | apomorphine |
| 4 | apolipoprotein E |
| 4 | antipsychotics |
| 4 | Walking |
| 4 | Ubiquitin-Protein Ligases (genetics) |
| 4 | UPDRS = Unified Parkinson's Disease Rating Scale |
| 4 | Tremor (therapy) |
| 4 | Transcription factor |
| 4 | Thiazoles (pharmacology) |
| 4 | TH, tyrosine hydroxylase |
| 4 | Supranuclear ophthalmoplegia |
| 4 | Supranuclear Palsy, Progressive (diagnosis) |
| 4 | Subthalamic Nucleus (physiopathology) |
| 4 | Substantia Nigra (metabolism) |
| 4 | Statistics, Nonparametric |
| 4 | Single-Blind Method |
| 4 | STN = subthalamic nucleus |
| 4 | Regression Analysis |
| 4 | Reference Values |
| 4 | Randomized Controlled Trials as Topic |
| 4 | Psychomotor Performance (physiology) |
| 4 | Postural Balance |
| 4 | Postoperative Complications (physiopathology) |
| 4 | Polymorphism, Genetic (genetics) |
| 4 | Placebos |
| 4 | Placebo |
| 4 | Peptide Fragments (cerebrospinal fluid) |
| 4 | Parkinson's Disease |
| 4 | Parkinson Disease, Secondary (diagnosis) |
| 4 | Parkinson Disease (rehabilitation) |
| 4 | Parkinson Disease (classification) |
| 4 | Neuroprotective Agents (adverse effects) |
| 4 | Neuroprotection |
| 4 | Neurons (pathology) |
| 4 | Neurons (drug effects) |
| 4 | Nerve Degeneration (pathology) |
| 4 | Multiple System Atrophy (physiopathology) |
| 4 | Movement |
| 4 | Movement disorders |
| 4 | Movement Disorders (genetics) |
| 4 | Movement Disorders (etiology) |
| 4 | Motor fluctuations |
| 4 | Mice, Inbred C57BL |
| 4 | MSA |
| 4 | MSA, multiple system atrophy |
| 4 | MRI, magnetic resonance imaging |
| 4 | Locus niger |
| 4 | Linkage |
| 4 | Lewy body disease |
| 4 | Late |
| 4 | Involuntary movement |
| 4 | Instrumentation therapy |
| 4 | Instrumental stimulation |
| 4 | Indans (therapeutic use) |
| 4 | Gilles de la Tourette syndrome |
| 4 | Genetic Association Studies |
| 4 | Gait (physiology) |
| 4 | Functional Laterality (physiology) |
| 4 | Fluctuations |
| 4 | Family Health |
| 4 | FP‐CIT SPECT |
| 4 | Evaluation scale |
| 4 | Electrodes, Implanted |
| 4 | Electric Stimulation |
| 4 | Early Diagnosis |
| 4 | Double blind study |
| 4 | Dopamine (physiology) |
| 4 | Dominance, Cerebral (physiology) |
| 4 | DNA-Binding Proteins (genetics) |
| 4 | DBS, deep brain stimulation |
| 4 | DA |
| 4 | Cell Line, Tumor |
| 4 | Carbidopa (adverse effects) |
| 4 | Canada |
| 4 | Bromocriptine |
| 4 | Basal ganglia |
